Novo Nordisk hopes to begin approval process of once-weekly insulin in H1 2023

Another round of positive study data for insulin icodec has cemented the company’s belief that a global approval process can be initiated at the start of next year, Novo Nordisk executive Martin Holst Lange tells MedWatch.

Martin Holst Lange, executive vice president for Development at Novo Nordisk | Photo: Novo Nordisk / PR

If everything pans out for Novo Nordisk in the near future, Denmark’s biggest pharmaceutical company expects to initiate a global application process for once-weekly insulin icodec in the first half of 2023, Executive Vice President for Development at Novo Nordisk Martin Holst Lange tells MedWatch.

This announcement came shortly after Novo Nordisk presented phase IIIa data from a study of the once-weekly insulin product on Thursday. All that’s left from the company’s Onwards program is now one single study, and Holst Lange says results are just around the corner.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs